Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02834247 · ClinicalTrials.gov registry record · Phase 1
A Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid Tumors
A Phase 1 study, sponsored by Calithera Biosciences.
- Terminated
- Registry status
- Phase 1
- Development phase
- 41
- Enrollment target
NCT02834247: Clinical Trial Phase 1 study, sponsored by Calithera Biosciences.
NCT02834247 is a Phase 1 study that was terminated before completion, run by Calithera Biosciences. The registered enrollment target is 41 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (32% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02834247, a Phase 1 study, was terminated before completion, sponsored by Calithera Biosciences.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 41 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D), safety and efficacy of TAK-659 in combination with nivolumab in participants with advanced solid tumors.
Primary Outcome
The MTD was defined as the dose range at which less than or equal to (\<=) 1 of 6 evaluable participants experience dose limiting toxicities (DLT) within the first 28 days of treatment (end of Cycle 1). Toxicities were evaluated according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03.
Interventions
- DRUG Nivolumab
- DRUG TAK-659
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2016-08-12 |
| Est. Completion | 2018-11-30 |
| Phase | Phase 1 |
Why NCT02834247 stopped before completion
NCT02834247 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 41 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (32% lower).
The record links to 0 conditions, and to 2 interventions - of which Nivolumab is the first listed.
NCT02834247 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02834247 about?
NCT02834247 is a clinical study titled "A Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid Tumors". The purpose of this study is to evaluate the maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D), safety and efficacy of TAK-659 in combination with nivolumab in participants with advanced solid tumors.
What is the current status of trial NCT02834247?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 41 participants. The study started on 2016-08-12. Estimated completion is 2018-11-30.
What interventions are being tested in trial NCT02834247?
The interventions under investigation include: Nivolumab (DRUG), TAK-659 (DRUG).
Who is sponsoring clinical trial NCT02834247?
This trial is sponsored by Calithera Biosciences, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02834247's enrollment target sits among peer trials
41 1125th of 2000 higher than 871 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03449238 · 41 participants · Phase 1
Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients
- NCT03900793 · 41 participants · Phase 1
Losartan + Sunitinib in Treatment of Osteosarcoma
- NCT04082520 · 41 participants · Phase 2
Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy
- NCT04220190 · 41 participants · Phase 2
RAPA-501 Therapy for ALS
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI